ABN guidance on COVID19 and MS therapies
11 March 2020
Coronavirus (COVID 19) has dominated headlines in recent weeks, with the number of cases in the UK continuing to rise. Older people and those with pre-existing medical conditions are more likely to become severely ill.
Our understanding of coronavirus is developing rapidly but there is concern that a variety of immunosuppressive therapies used in the treatment of a range of neurological disorders might predispose patients to contract coronavirus or increase the severity of infections.
The ABN MS and Neuroimmunology Advisory Group has prepared advice on the use of MS treatments based on current knowledge. This guidance will be kept under review as our understanding of the virus develops. Further guidance on the use of other immunosuppressive therapies for a range of immunological conditions will be issued shortly.
To view the guidance please click here.